Active B12 Test Market Trends

Global Active B12 Test Market Overview

Active B12 Test Market Size was valued at USD 3.2 Billion in 2022. The Active B12 Test market industry is projected to grow from USD 3.42 Billion in 2023 to USD 5.93 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 16.26% during the forecast period (2023 - 2032). Increased health concerns and deficiency of vitamin B12 are the prime factors that are acting as the key market drivers enhancing the market growth.

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Active B12 Test Market Trends

• Growing B12 Vitamin Deficiency Diseases is driving the market growth

Market CAGR for the active B12 test market is being driven by the rising deficiency diseases of vitamin B12. Due to the rising count of cases of macrocytic Lancia-related conditions, such as folic acid deficiency or vitamin B12 deficiencies among adults across many regions of the world, end-users like physicians, hospitals, and diagnostic laboratories have been paying close attention to the Active B12 Test, a type of blood test. Over the projected period, this factor is anticipated to fuel regional expansion. In addition, the increasing occurrence of macrocytic Lancia in pregnant women as a result of inadequate dietary intake during pregnancy may potentially feed demand in terms of value & volume.

Furthermore, due to rising consumer awareness of folate insufficiency, pernicious anemia, and the prevalence of macrocytic Lancia in adults, the global market for active b12 tests has been expanding steadily. escalating demand for folic acid food fortification. Thus, driving the Active B12 Test market revenue.

Active B12 Test Market Segment Insights

Active B12 Test Type Insights

The Active B12 Test Market segmentation, based on type includes Elisa Assay, Enzyme Immunoassay, and Others. The enzyme immunoassay segment dominated the market. The analytical method known as the enzyme immunoassay (EIA) is frequently employed in medical research and diagnosis. To specifically identify the presence of antigen or antibody in a sample, it depends on an enzyme-antibody reaction. Due to its simplicity of use, cheap cost, and high throughput capacity, EIA has been widely used as a clinical assay method for standard diagnosis by numerous businesses worldwide.

Active B12 Test Application Insights

The Active B12 Test Market segmentation, based on application, includes Folate Deficiency Anemia, Pernicious Anemia, Macrocytic Anemia, and Others. The macrocytic anemia category generated the most income. A test known as an active B12 test is done to determine whether or not your body has adequate vitamin B-12. Large red blood cells in the body are a sign of macrocytic anaemia, which is brought on by lower levels of vitamin b-12 and folic acid (vitamin b). If macrocytic anaemia is not promptly recognised and treated with the appropriate supplements, it could be hazardous for the patients who have it.

Figure 1: Active B12 Test Market, by Application, 2022 & 2032 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Active B12 Test Regional Insights

By region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American Active B12 Test market area will dominate this market, owing to an rising awareness regarding folate deficiency. In addition, the growing number of macrocytic lancia will boost market growth in this region.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2: Active B12 Test Market Share By Region 2022 (USD Billion)

Source: Secondary Research, Primary Research, MRFR Database and Analyst Review

Asia Pacific Active B12 Test market accounts for the second-largest market share owing to the rising development of clinical laboratories as well as the rise in geriatric population. Further, the Chin Active B12 Test market held the largest market share, and the Indian Active B12 Test market was the fastest growing market in the European region

The Europe Active B12 Test Market is expected to grow at the fastest CAGR from 2023 to 2032. The growth is attributed to the increase in healthcare expenditure by the government. Moreover, Germany’s Active B12 Test market held the largest market share, and the UK Active B12 Test market was the fastest growing market in the Asia-Pacific region.

Active B12 Test Key Market Players & Competitive Insights

Leading market players are investing heavily in research & development activities in order to expand their product lines, which will help the Active B12 Test market, grow even more. Market players are also undertaking a variety of strategic activities to expand their global footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, Active B12 Test industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the global Active B12 Test industry to benefit clients and increase the market sector. In recent years, the Active B12 Test industry has offered some of the most significant advantages to medicine. Major players in the Active B12 Test market, including Axis Shield Diagnostics Ltd., Abbott, Siemens Healthcare Private Limited., DiaSorin S.p.A., F. Hoffmann La Roche Ltd., LifeSpan BioSciences, Inc., Demeditec GmbH, and others, are trying  to increase market demand by investing in research and development operations.

The Italian firm DIESSE Diagnostica Senese Società Benefit S.p.A. manufactures integrated and totally internal in-vitro diagnostic systems. Its main office is in Siena. The company has created, produced, and sold cutting-edge diagnostic systems ever since it was founded in 1980, primarily in the areas of immunodiagnostics and automated ESR measurement. The business has presence over than 100 countries, has three production facilities, and one research facility. DIESSE is recognised as an example of true "Diagnostics Evolution" because it combines cutting-edge technology, Italian design, and new automated diagnostic detection tools. In October 2022, By the end of November, two new tests for vitamin B12 and folate will have been available, according to DIESSE Diagnostica Senese. Quantification of vitamin B12 and folate is crucial for determining the reasons of anaemia or neuropathy, assessing some patients' nutritional condition, and determining how well these vitamins are being treated. These additional kits will be accessible on CHORUS systems as mono-tests, enhancing the more than 150 tests currently offered in the instrument's analytic menu.

A company called DiaSorin SpA (DiaSorin) specialises in the research, production, and marketing of systems and kits for in vitro diagnostic reagents. In order to enable automatic diagnostic examination, the company creates reagent kits based on ELISA and CLIA procedures. It is possible to diagnose infectious diseases, bone and mineral problems, endocrinology, hypertension, cancer, gastrointestinal infections, autoimmune disorders, neurological and cardiac diseases, among other conditions, using the company's immunodiagnostic and molecular diagnostics tools. Distributors and direct sales representatives are how DiaSorin markets its goods. It conducts business throughout Asia, Europe, the Middle East, South Africa, North America, and South America. The headquarters of DiaSorin are in Saluggia, Piemonte, Italy. In July 2021, Luminex Corporation has been acquired by DiaSorin S.p.A. ("DiaSorin"; FTSE MIB: DIA) at a price of USD 37.00 per share, equating to a total equity value of roughly USD 1.8 billion. In addition to strengthening its current offering, DiaSorin will have access to Luminex's multiplexing technology through the acquisition, which will also increase the Group's footprint in the United States.

 Key Companies in the Active B12 Test market include

• Axis Shield Diagnostics Ltd.


• Abbott


• Siemens Healthcare Private Limited.


• DiaSorin S.p.A.


• Hoffmann La Roche Ltd.


• LifeSpan BioSciences, Inc.


• Demeditec GmbH

Active B12 Test Industry Developments

August 2021: The makers of nutritional status tests for omega-3 fatty acids and vitamin D, OmegaQuant, have announced the availability of a new test to determine vitamin B12 status that consumers may take at home. The practical test detects methylmalonic acid (uMMA), which OmegaQuant claims is the most precise approach to assess poor B12 status. A person is more likely to be deficient in this nutrient if you have more uMMA.

Active B12 Test Market Segmentation

Active B12 Test Type Outlook

• Elisa Assay


• Enzyme Immunoassay


• Others

Active B12 Test Application Outlook

• Folate Deficiency Anemia


• Pernicious Anemia


• Macrocytic Anemia


• Others

Active B12 Test Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America